FDA approves FET-PET agent for glioma - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves FET-PET agent for glioma

The radioactive diagnostic drug is indicated in patients aged 1 month or older and is used in conjunction with other diagnostic evaluations.

  • By

  • Kathryn Wighton

  • September 14, 2026

  • 2 min

Share

Original Source(s)

FDA approves FET-PET agent for glioma

  • by Kathryn Wighton

  • September 14, 2026

Related Content

FDA approves tau PET imaging agent

The F18-labeled agent is indicated for brain PET imaging to identify tau neurofibrillary tangle pathology.

Body Dysmorphic Symptoms Linked to Brain Structure

Researchers reported gender-specific associations in visual and limbic brain regions among healthy adults with subclinical body dysmorphic symptoms.

Handwriting Kinematics Differentiate Cognitive Impairment

“Diagnostic differentiation emerged only under tasks imposing higher cognitive-motor demands.”